-- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an updated objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria – - ...
Hosted on MSN
Thinking of migrating? Think again
ARE the Senate shenanigans and prospects of unbridled corruption now and in the next six years after the 2028 presidential election forcing you to choose to be here — or there? For skilled workers and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results